lunes, 14 de abril de 2014

Cancer therapy resistance: chasing epigenetics : Nature Medicine : Nature Publishing Group

Cancer therapy resistance: chasing epigenetics : Nature Medicine : Nature Publishing Group



Cancer therapy resistance: chasing epigenetics

Nature Medicine
 
20,
 
340–341
 
 
doi:10.1038/nm.3528
Published online
 
Dr. Gopal Murti / Science Source
Resistance to targeted cancer therapies is a challenge to their successful application. T cell acute lymphoblastic leukemia (T-ALL) has been found to be associated with activation of the signaling protein NOTCH1; however, clinical success of NOTCH1-targeted therapies has been transient, probably owing to the development of drug resistance. Knoechel et al.1

No hay comentarios:

Publicar un comentario